VectorLogics Overview

  • Founded
  • 1999
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

VectorLogics General Information


Developer of virus based cancer therapies and therapeutic vaccines for viral liver diseases. The company utilizes IBDV technology for research on Viral hepatitis and Hepatocellular carcinoma. The company commercializes products for Cancer Virotherapy, Cancer Vaccines, Prophylactic and Therapeutic Vaccines.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 550 11th Street South
  • Birmingham, AL 35294
  • United States
+1 (301) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

VectorLogics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 23-Oct-2012 Completed
10. Grant 22-Jul-2009 00000 Completed
9. Grant 17-Sep-2008 00000 Completed
8. Grant 21-Feb-2008 00000 Completed
7. Grant 01-Jan-2008 00000 Completed
6. Grant 01-Jan-2007 00000 Completed
5. Grant 01-Jan-2006 00000 Completed
4. Grant 01-Jan-2002 00000 Completed
3. Grant 01-Jan-2001 $170K Completed
2. Grant 01-Jan-1999 $350K Completed
To view VectorLogics’s complete valuation and funding history, request access »

VectorLogics Executive Team (2)

Name Title Board Seat Contact Info
David Curiel Ph.D Chief Scientific Officer & Founder
To view VectorLogics’s complete executive team members history, request access »

VectorLogics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Greer Capital Advisors Venture Capital Minority 000 0000 000000 0
To view VectorLogics’s complete investors history, request access »